Jonathan Mahler’s article in the Sept. 14 issue of The New York Times Magazine provided an excellent overview of the Trump administration’s assault on cancer research.
Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.
